Piper Sandler lowered the firm’s price target on Amgen (AMGN) to $328 from $329 and keeps an Overweight rating on the shares. The firm notes that monthly third-party prescription data for April 2025 are now available. The volume growth trajectory for Repatha and Tezspire remains aggressive, and these dynamics are key components of Piper’s constructive thesis on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Biotech Alert: Searches spiking for these stocks today
- Cautious Hold on Amgen: Navigating Competitive Challenges and Market Potential for MariTide
- Amgen Stock May Get Fatter Premiums As It Slims Down Obesity Drug Competition with MariTide
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
- Amgen downgraded to Hold from Buy at Erste Group